Navigation Links
First targeted nanomedicine to enter human clinical studies
Date:4/4/2012

m2 and dose escalation is ongoing. It has been well-tolerated with no new toxicities observed.

"It has been a privilege to be a part of the team that developed this technology at its conception through its clinical translation. The emerging BIND-014 clinical data showing signals of efficacy even at relatively low doses validates the potential for the revolutionary impact of nanomedicines and is a paradigm shift for the treatment of cancer." said Philip W. Kantoff, MD, Chief Clinical Research Officer at DFCI, Professor of Medicine at Harvard Medical School, and study co-author.

"It is wonderful to witness a world-class team of scientists, engineers, physicians, for-profit and non-project organizations converge to develop this potentially revolutionary technology for treatment of cancers. The effectiveness of this team has been remarkable and serves as model for translational research" said Edward J. Benz, Jr. MD, President of DFCI, Richard and Susan Smith Professor of Medicine at Harvard Medical School.

The research and development of the first targeted programmable nanomedicine to show anti-tumor effects in humans represents the culmination of more than a decade of investigation initially carried out in academic labs at BWH and MIT, and supported by funding from the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, The David H. Koch Institute for Integrative Cancer Research at MIT, the Prostate Cancer Foundation, philanthropic gift from David H. Koch, and the Dana-Farber Harvard Cancer Center Prostate Cancer SPORE; and subsequently carried out in the laboratories of BIND Biosciences leading to the development of BIND-014, and supported by funding from the National Cancer Institute, National Institute of Standards and Technology and BIND Biosciences.

BIND Biosciences was launched in 2007 based on technologies that were licensed from BWH and MIT and developed, respectively, in the laborator
'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. First Bedside Gene Test Shows Promise
2. Complications in patients undergoing PCI tend to occur within first 30 days
3. $4.2 million grant helps plan, launch first Alzheimers prevention trials
4. First national guideline for sudden hearing loss published
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. First study of its kind finds no increased risk of heart disease for kidney donors
7. UC San Diego among first in nation to treat brain cancer with novel viral vector
8. First breakdown of public health data for Cleveland neighborhoods
9. Rapid Flu Tests a Good First Step: Study
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Mount Sinai first to use visually guided catheter ablation system to treat AFib patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... San Mateo, CA (PRWEB) July 25, 2014 ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , For more than ... and the Bay Area community through its residential alcohol ... Innovations will educate on Project Ninety's humble idea and ...
(Date:7/25/2014)... July 25, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... be supporting senior-led projects in Alberta through their New ... for Seniors Program is a federal grants and contributions ... who make a difference in the lives of others ...
(Date:7/25/2014)... Ca (PRWEB) July 25, 2014 The ... with their Anniversary Futon Sale. The Futon Shop has been ... pop shop, which has grown from a few handmade futon ... 33 different kinds of futon mattresses. , The Futon ... the beginning and the desire to sleep on natural fibers ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry leader ... and services for infectious disease diagnostic development, is ... Multimarker Controls - MDZ001 . , An ... marked, unassayed external run control intended for use ... Multimarker Controls - MDZ001 has been specifically designed ...
Breaking Medicine News(10 mins):Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
... protecting children from flu if they included both strains of ... has found. "Adding a second influenza B virus strain ... guesswork out of strain selection and help improve the vaccine,s ... and director of the Center for Vaccine Development at Saint ...
... ... Wigix Inc.’s subsidiary, ddku.com, affording it an end to end marketing platform in China. ... Oakland, CA ... has acquired a Shanghai-based business process outsourcing company, Mag2U, to enhance DDKU’s growing internet ...
... testing, experts say , TUESDAY, April 6 (HealthDay News) -- ... have a genetic mutation that boosts their risk for the ... breast than are women who don,t have the genetic mutations, ... these women, who carry a mutation in the BRCA1 and ...
... Today, the Interactive Autism Network (IAN), www.ianproject.org, the ... of the Grandparents of Children with Autism Spectrum ... who participated were the first to raise concerns ... 2007, the IAN Project has helped to accelerate ...
... Indianapolis, 6 April, 2010 The global nursing shortage is ... schools and to a phenomenon known as nurse migration, where ... response, the International Council of Nurses (ICN) and the Honor ... The Elsevier Foundation, will conduct the Global Summit on Nurse ...
... April 2010 - Attention-deficit/hyperactivity disorder (ADHD) is one of ... adolescents. Children with ADHD are excessively restless, impulsive, and ... Problems inhibiting behavior are a common theme for ADHD ... medications, behavioral approaches or a combination of the two. ...
Cached Medicine News:Health News:Building a better flu vaccine: Add second strain of influenza B 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 2Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 3Health News:New survey finds grandparents play key role in lives of children with autism 2Health News:New survey finds grandparents play key role in lives of children with autism 3Health News:International summit seeks solutions to global shortage of nursing faculty 2Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Pa., April 23 Wyeth,Pharmaceuticals, a division of ... it,is withdrawing its application for an extension to ... sought approval,of TYGACIL for the treatment of community-acquired ... of the Committee for Medicinal,Products for Human Use ...
... an Investigational Drug for Duchenne/Becker ... Muscular Dystrophy, ... announced the initiation of an international pivotal trial of,PTC124 in patients ... objective of this registration-directed,Phase 2b trial is to demonstrate the efficacy ...
Cached Medicine Technology:More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 2More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 3More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 4More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 5PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: